BioFocus management team celebrate commencement of works with first site visit.
Site clearing work has begun to make way for BioFocus’ state-of-the-art laboratory and HQ facility – The Robinson Building. On completion, the 60,000 sq ft (5,587 sq m) building, which will unite the majority of the company’s drug discovery groups, will afford BioFocus a unique position amongst drug discovery CRO’s for the support of integrated projects.
To celebrate ‘breaking ground’ members of the Management Team from BioFocus, accompanied by Julian Cobourne of Aviva Investors, owners of Chesterford Research Park and Martin Sylvester of Churchmanor Estates, the joint developers, together with representatives from the design and construction teams gathered on site for a first look at progress to date.
Chris Newton, Managing Director of BioFocus commented: “The importance of this new building cannot be underestimated from our perspective. The ability to bring our biology and medicinal chemistry teams together within this contemporary, highly efficient new HQ will bring added synergies both to our clients and our scientists. Marking the beginning of the build-phase is a very exciting day for us.”
On completion the building will comprise two wings, linked by a dramatic two-storey atrium with landscaped courtyard behind. An attractive curved profile will be further enhanced by extensive green landscaping, ensuring the building sits unobtrusively within the Park’s naturally beautiful surroundings.